甲磺酸阿帕替尼治疗进展期胃癌的研究进展

胃癌是全球最常见的恶性肿瘤之一，其早期发现困难，发现时大多已失去手术机会。当前，全身综合治疗是进展期胃癌的主要治疗方法，但是，由铂类和氟尿嘧啶类联合为代表的标准化疗方案对于进展期胃癌的疗效欠佳。随着靶向药物的不断研究和发展，靶向药物在进展期胃癌治疗中占据了越来越重要的地位。甲磺酸阿帕替尼是我国自主研发并应用的一种小分子血管内皮生长因子(vascular endothelial growth factor,VEGF)受体抑制剂，高度选择性地竞争细胞内VEGF-2的三磷酸腺苷(adenosine triphosphate,ATP)结合位点，抑制肿瘤组织新生血管形成，进而抑制肿瘤组织的发生发展。本文系统地阐述了甲磺酸阿帕替尼治疗进展期胃癌的研究现状与进展，旨在为其进一步的临床应用提供参考依据。

Progress of apatinib in the treatment of advanced gastric cancer

Gastric cancer is one of the most common malignant tumors in the world. Early diagnosis is difficult and most patients have missed the best timing of surgery when diagnosed. Therefore, systemic comprehensive therapy should be the best treatment option for advanced gastric cancer. Recent years, the standard chemotherapy regimen, such as platinum and fluorouracil-based regimen has been proven poor efficacy. However, with continuous research and development, the role of targeted drugs has become increasingly important in the treatment of advanced gastric cancer. Apatinib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor developed and applied in China, which highly selectively competes with the binding site of adenosine triphosphate (ATP) of VEGF-2 in cells, inhibits the formation of new blood vessels in tumor tissues, and then inhibits the occurrence and development of tumor tissues. This article systematically reviewed the current research status and progress of apatinib in the treatment of advanced gastric cancer in order to provide a reference for further clinical application.